BTD

Across TCGA pan-cancer cohorts, BTD mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BTD’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BTD mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BTD is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and CCRCC are the cancer types where BTD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−1.150	<.001	12	view →
COAD	Male	II,III,IV	−0.745	<.001	11	view →
CCRCC	Male	III,IV	−0.715	<.001	11	view →
LSCC	Female	All	−1.113	<.001	9	view →
LUAD	Female	III,IV	−0.923	<.001	9	view →
PDAC	Female	III,IV	−0.496	.007	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BTD–HNSC

Open the HNSC breakdown →